Bio-Rad Laboratories, Inc. (BIO) AI Stock Analysis

Bio-Rad Laboratories, Inc. is a manufacturer and distributor of life science research and clinical diagnostic products across the United States, Europe, Asia, Canada, and Latin America. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments for proteomics, genomics, cellular biology, and food safety. Its customers include universities, medical schools, pharmaceutical manufacturers, biotechnology researchers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories, serving hospital, reference, newborn screening, and transfusion laboratories.

Bio-Rad's revenue moved from $2.92B in FY2021 to $2.58B in FY2025, recording a 5-year revenue CAGR of 0.3%. Annual revenue contracted 4.1% in FY2022, 4.7% in FY2023, and 3.9% in FY2024 before growing 0.7% in FY2025. Gross margins declined from 56.1% in FY2021 to 52.0% in FY2025, while operating margin fell from 17.1% to 10.5%. Net income rebounded to $759.9M in FY2025 following GAAP losses in FY2022, FY2023, and FY2024. For the latest quarter ended June 30, 2026, quarterly revenue fell 0.1% year-over-year while quarterly earnings grew 18.7%. Trailing twelve-month revenue stands at $2.59B with diluted EPS of $7.89.

As of June 30, 2026, Bio-Rad held $1.62B in cash and short-term investments against $1.20B in total debt, resulting in net cash of $414.8M. The company maintains a current ratio of 3.14 and a debt-to-equity ratio of 0.17 on $7.17B of shareholders' equity. In FY2025, operating cash flow reached $532.2M and free cash flow was $374.6M after capital expenditures of $157.6M. Capital allocation in FY2025 included $295.5M deployed toward share buybacks, contributing to a 10.4% reduction in share count over 5 years.

At $353.70 per share, Bio-Rad carries a market cap of $9.46B and an enterprise value of $9.81B. The stock trades at a trailing P/E of 44.8x and a forward P/E of 41.3x, both higher than the US-listed Healthcare median of 24.6x trailing and 17.3x forward. Its enterprise value-to-EBITDA ratio is 17.3x compared to the peer median of 12.0x, while its price-to-sales multiple is 3.7x versus the peer median of 4.1x. Over the 1-year period, BIO returned 13.2% compared to 16.8% for the S&P 500 benchmark, while its 5-year return of -51.0% lagged the S&P 500's 83.0% gain.

Wall Street coverage includes 3 analysts: 1 Buy, 1 Hold, and 1 Sell. The mean price target is $335.00, which is 5.3% below the last close of $353.70. For the fiscal year ending December 31, 2026, analysts estimate revenue of $2.57B and EPS of $9.45, reflecting a 4.7% earnings contraction. For the next fiscal year, consensus expects revenue to grow 2.1% to $2.62B with EPS of $9.75. The company beat EPS estimates in 2 of the last 4 quarters, and the next earnings date is November 4, 2026.

This page is an AI-written research summary of Bio-Rad Laboratories, Inc. (BIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BIO income statement, BIO balance sheet, BIO key metrics, BIO analyst forecast, BIO chart. See the BIO stock overview for the latest quote and news.